Repurposing clinically safe drugs for DNA repair pathway choice in CRISPR genome editing and synthetic lethality.

Nat Commun · 2025 · PMC12698765 · PMID 41372233

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In line with knock-down by siRNA, treatment with the calcium channel blocker drug nicardipine 55 or AOX1 inhibitor drug raloxifene 56 also showed a trend towards increased HDR when combined with M3814 (Fig. 3h ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.